For over 25 years, Biosensors International Group has been developing and researching catheter systems for intensive care and related devices used during cardiac surgeries and intensive care treatments.

Constantly striving to be at the forefront of innovative products, with a particular focus on improving patient outcomes today, Biosensors is a driving force in the development of next-generation medical technologies.

In 2000, Biosensors entered the interventional cardiology market and immediately became the first cardiology company to develop and patent its own proprietary Limus agent, Biolimus A9™ (BA9™), a highly lipophilic anti-restenosis drug designed for cardiovascular stent technologies.

Biosensors was also the first stent manufacturer to develop and launch a biodegradable polymer stent, with only the abluminal side coated with polymer and drug to reduce systemic impact.
Over the past two decades, Biosensors has become one of the largest manufacturers and suppliers of cardiovascular stents worldwide.
Biosensors' products for interventional cardiology are designed to optimize patient treatment outcomes.